Propranolol for the Treatment of Hemangioma in PHACE Syndrome: A Case Report.
cleft lip
dandy-walker
hemangioma
phace syndrome
propranolol
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
accepted:
24
08
2023
medline:
28
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
Oral propranolol is commonly used as a first-line treatment for infantile hemangioma. However, its use in PHACE (posterior fossa anomalies, hemangioma, arterial anomalies, cardiac anomalies, and eye anomalies) syndrome raises concerns that it might exacerbate the patient's risk of stroke. Here, we report the case of a four-month-old premature girl with PHACE syndrome, who presented with a large hemangioma involving the left side of her face, following the V1+V2+V3 distribution, including the upper lip, left ear, and left eye. This condition was successfully treated with propranolol, and no adverse side effects were reported.
Identifiants
pubmed: 37638272
doi: 10.7759/cureus.44036
pmc: PMC10457131
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e44036Informations de copyright
Copyright © 2023, Beidas et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
JAMA Dermatol. 2020 Feb 1;156(2):186-190
pubmed: 31825455
An Bras Dermatol. 2018 Jun;93(3):405-411
pubmed: 29924216
Int J Dermatol. 2015 Jan;54(1):102-7
pubmed: 24962639
Neuroradiology. 2004 Mar;46(3):227-33
pubmed: 14758450
Pediatr Dermatol. 2013 Jan-Feb;30(1):71-89
pubmed: 22994362
Br J Dermatol. 2015 Jul;173(1):242-6
pubmed: 25639889